The Microbiome Therapeutics Innovation Group (MTIG) announced the publication of its Position Statement on Fecal Microbiota Transplantation (FMT) treatment. The statement supports the FDA Draft Guidance providing for patient access to FMT treatment through clinical […]
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research and […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with […]
SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge (Copenhagen) and LSP (Amsterdam), together with North-East […]
L’Oréal announced a partnership between its Technology Incubator and Silicon Valley-based uBiome, the leader in microbial genomics, to continue its longtime research into skin microbiome—the trillions of bacteria that live on, and provide an important […]
Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, announces it has completed the first closing of its second dedicated fund focused on the microbiome, and health, […]
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, announced the pricing of its initial […]
Pivot Bio announced it is named to Fast Company’s annual list of the World’s Most Innovative Companies in 2019. The company was recognized for its transformational work in agriculture, earning Pivot Bio the eighth spot […]
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative and neuropsychiatric diseases, today announced the completion of a $25 million series B equity financing. New investor Seventure Partners, […]
Acurx Pharmaceuticals, LLC (“Acurx” or the “Company”), a privately-held, clinical stage, biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced today that its lead product candidate, ACX-362E, has successfully completed the 32-subject, double-blinded, placebo-controlled, […]
KNOW Bio, LLC., (the Company), a North Carolina developer of nitric oxide-based medical technology and related biotechnology companies, announced that the Company has formed a new wholly-owned operating subsidiary, Digestive Health Therapeutics, Inc, to develop […]